Max Kepler's Free Agency Plummets: 80-Game MLB Suspension for Performance-Enhancing Substance
The baseball world is abuzz with the news that Max Kepler's free agency journey has taken a dramatic turn for the worse. The 32-year-old outfielder, who was a key player in the Phillies' NLDS run last season, is now facing a significant setback due to a performance-enhancing drug violation.
On Friday, the MLB announced that Kepler has been suspended for 80 games for testing positive for Epitrenbolone, an anabolic steroid not approved for human use. This suspension, which covers half of the 2026 season, is a harsh blow to Kepler's prospects in the free agency market.
Trenbolone, the substance in question, is primarily used to promote muscle growth in cattle and carries no medical approval for human consumption. The suspension is a stark reminder of the MLB's zero-tolerance policy towards performance-enhancing drugs.
Prior to his suspension, Kepler had a calculated market value of just under $7.6 million, based on a one-year, $10 million deal with the Phillies. However, this suspension will undoubtedly impact his value, potentially affecting his future earnings and market standing.
In the 2023 season, Kepler played 127 games, posting a slash line of .216/.300/.391 with 18 home runs and 52 RBIs. His performance, while not exceptional, was still respectable, and he was a key contributor to the Phillies' playoff push.
Kepler's journey in the MLB began with the Twins in 2015, where he played for 10 seasons, including two ALDS appearances. This suspension marks a significant challenge for the veteran outfielder, who is now entering his 12th season in the league.
